Thanks for repeating exactly the same comments on here for about the 100th time in the last year .... I am not sure the mum and dad investors heard you ?
You seem to think it is all over in relation to the use of Remestemcel-L to treat COVID-19 ARDS and ARDS in general ...
...... reporting from the company this week shows otherwise .... unless of course you think with the ambulance chasers sitting in the background that the company is likely to be misleading the market at this time - 31 May 2022 ?
... and let's face it, the NIH paid out ~$50m USD for the trial so Mesoblast is in front however you look at it - additional Remestemcel-L data, a new indication in their pipeline, etc etc ... all which cost them very little money
RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-432
-
- There are more pages in this discussion • 474 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |